ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells CGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally.
The last earnings update was 16 days ago.
Discounted Cash Flow Calculation for TSEC:1789 using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
Note: Free cash flow to equity valuations ignore the company's cash or debt.
TSEC:1789 DCF 1st Stage: Next 10 year cash flow forecast
The current share price of
is above its future cash flow value.
Often investors are willing to pay a
for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
ScinoPharm Taiwan's earnings available for a low price, and how does
this compare to other companies in the same industry?
ScinoPharm Taiwan's earnings are expected to grow significantly at over 20% yearly.
ScinoPharm Taiwan's revenue is expected to grow by 10.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
ScinoPharm Taiwan's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
ScinoPharm Taiwan's finances.
The net worth of a company is the difference between its assets and liabilities.
ScinoPharm Taiwan is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
ScinoPharm Taiwan's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
ScinoPharm Taiwan's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 23.1x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Tsung-Ming Su, also known as Tony, MBA has been President and Chief Executive Officer at ScinoPharm Taiwan, Ltd. July 05, 2018. Mr. Su serves as President of President International Development Corp., President Life Sciences Co., Ltd., President Property Corporation. Mr. Su has been Senior Vice President of Uni-President Enterprises Corporation since May 1, 2008. He served as Director of Finance Group at Uni-President Enterprises Corporation from August 01, 2002 to July 01, 2017. He serves as Vice President and Chief Financial Officer of Uni-President Group. He serves as Supervisor of Grand Bills Finance Corp., Nanlien International Corp., Presco Netmarketing Inc., PresidentTokyo Corp. and President Tokyo Auto Leasing Corp. He served as Vice President of Uni-President Enterprises Corp., since April 16, 2007 and also served as its Assistant Vice President from August 1, 2000 to April 16, 2007. He has over 22 years of experience in banking and financial management. Prior to joining Uni-President Group in August 2000, he served as Vice-President of the Taipei branch of Citibank. He was the financial specialist of Seibu Department Store in Tokyo in 1988 and the senior specialist of Nortel Networks Asia/Pacific in Tokyo in 1990. He has been Representative Director of President Chain Store Corp. since February 14, 2008. He serves as a Director of Grand Bills Finance Corp. and has been Representative Director of ScinoPharm Taiwan, Ltd. since July 6, 2010. He has been a Non Executive Director of Uni-President China Holdings Ltd., since August 8, 2007. Mr. Su holds an MBA from the Iowa State University.
Insufficient data for Tony to compare compensation growth.
Insufficient data for Tony to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the ScinoPharm Taiwan management team is over 5 years, this suggests they are a seasoned and experienced team.
Chairman & General Chief Strategy Officer
Senior Director of Finance
Vice President of Operations
Senior Director of Accounting
Vice President of Administration & Spokesperson
VP of Marketing & Sales and Chief Strategy Officer
Director of Human Resources & Administration
VP of Injectable Business Division & CSO
Board of Directors Tenure
Average tenure of the
board of directors in years:
The tenure for the ScinoPharm Taiwan board of directors is about average.
Board of Directors
Chairman & General Chief Strategy Officer
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells CGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. The company offers custom synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and brand company outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, exploratory process research, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates. In addition, the company develops peptide synthesis technologies. Further, it develops and manufactures Western medicines and other chemical materials, albumin medicines, oligonucleotide medicines, injections, and new small molecule drugs, as well as provides biological technology services and technical services. The company has a strategic partnership with Baxter International Inc. to develop, manufacture, and commercialize five injectable drugs used in a range of cancer treatments, including lung cancer, multiple myeloma, and breast cancer, as well as medication to treat nausea and vomiting, and common side effects of chemotherapy. ScinoPharm Taiwan, Ltd. was founded in 1997 and is headquartered in Tainan, Taiwan.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.